Siemens Share Price Under Pressure Amid Strategic Restructuring

Siemens posts record orders and raises 2026 EPS guidance, but investor skepticism grows over the planned reduction of its controlling stake in Siemens Healthineers.

Despite posting robust operational figures, Siemens is encountering skepticism in the equity markets. The source of investor concern appears to be a major strategic shift rather than the company's day-to-day performance, specifically the planned reduction of its controlling stake in Siemens Healthineers. This move raises questions about its timing for an industrial conglomerate that is simultaneously reporting record orders and executing a share buyback.

Elevated Guidance on Strong Quarterly Performance

Siemens began its 2026 fiscal year with solid growth. Group orders advanced by 10% to reach €21.4 billion, while revenue increased by 8%. The industrial business segment saw its profit climb 15% to €2.9 billion, achieving a margin of 15.6%. Adjusted earnings per share rose from €2.22 to €2.80.

A notable highlight was the order backlog, which hit a record €120 billion. With a book-to-bill ratio of 1.12, new orders are being received faster than the company can convert them into revenue, providing strong visibility for future quarters. The data center business was a particular standout, with revenue surging 35% driven by cloud demand in the United States.

On the strength of this start, management raised its full-year guidance. The forecast for adjusted earnings per share (before PPA) was lifted to a range of €10.70 to €11.10. Chief Financial Officer Ralf Thomas indicated that revenue growth is now expected in the upper half of the 6% to 8% target corridor. The company also plans a dividend of €5.35 per share, reaffirming its commitment to a progressive dividend policy even after the deconsolidation of Healthineers.

The Core Strategic Shift: Reducing the Healthineers Stake

The central strategic development is a board-approved plan to divest Siemens' majority holding in Siemens Healthineers. The current proposal involves a direct spin-off of approximately 30% of Healthineers shares to Siemens shareholders. This transaction would cause Siemens to lose its controlling interest, eventually retaining only a significant minority stake in the medical technology company.

The market is still digesting the implications, as numerous details remain to be finalized. Siemens intends to clarify the structure and timeline early in the second quarter of 2026. The plan will require approval from the shareholder meetings of both companies and must clear regulatory hurdles. According to the source material, this uncertainty is currently weighing on market sentiment.

Buyback Fails to Offset Share Price Weakness

Concurrently, Siemens is proceeding with capital measures, including a buyback program. In March, the company is set to cancel 18 million of its own shares, reducing the total number of outstanding shares to approximately 782 million. This action provides arithmetic support for earnings per share by distributing profits across a smaller share count.

In the near term, however, this has not buoyed the stock. Siemens shares currently trade at €216.95, reflecting a daily decline of 3.88%. Over the past 30 days, the stock has fallen 13.82% and sits roughly 13% below its 50-day moving average of €249.37. Beyond the transaction overhang, the source cites the geopolitical environment as an additional headwind.

Key milestones are now in focus. Siemens aims to provide detailed plans for the Healthineers transaction early in Q2 2026, followed by the release of its second-quarter results on May 13, 2026. At that juncture, the market will assess whether the high order momentum—especially within the data center segment—continues to deliver operationally as the corporate restructuring progresses.